Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-06-18

Clinical Trial Update: A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine [Phase 4]

View source ↗

Summary

Phase 4 study of galcanezumab in adults with episodic migraine has completed, and results were posted on 2024-06-18.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Galcanezumab (galcanezumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Migraine, Episodic Migraine | Phase 4 | Status: COMPLETED | Results posted: 2024-06-18